Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. A-a-1 Antibiotic
2. Bi 397
3. Bi-397
4. Bi397
5. Dalbavancin
6. Dalvance
7. Mdl 64,397
8. Mdl-64397
9. Ver-001
10. Ver001
11. Xydalba
12. Zeven
1. Dalbavancin (hydrochloride)
2. Ver 001
3. Ver-001
4. Dalbavancin Hcl
5. Chembl3301650
6. Dalbavancin Hydrochloride (5:8)
7. A-a 1
8. Cs-3579
9. Hy-17586
Molecular Weight | 1853.1 g/mol |
---|---|
Molecular Formula | C88H101Cl3N10O28 |
Hydrogen Bond Donor Count | 22 |
Hydrogen Bond Acceptor Count | 30 |
Rotatable Bond Count | 22 |
Exact Mass | 1850.585236 g/mol |
Monoisotopic Mass | 1850.585236 g/mol |
Topological Polar Surface Area | 573 Ų |
Heavy Atom Count | 129 |
Formal Charge | 0 |
Complexity | 3740 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01XA04
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36025
Submission : 2021-08-25
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-10-25
Pay. Date : 2021-09-14
DMF Number : 35874
Submission : 2021-04-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-01-18
Pay. Date : 2022-12-12
DMF Number : 37186
Submission : 2022-11-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37185
Submission : 2022-09-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-07-01
Pay. Date : 2021-05-10
DMF Number : 35428
Submission : 2021-01-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-23
Pay. Date : 2024-01-29
DMF Number : 39378
Submission : 2024-03-27
Status : Active
Type : II
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
About the Company : Founded in 1987, Transo-Pharm is a fully licensed and certified global distributor of pharmaceutical components for the health and veterinary industries. The company supports its c...
Comhony Biotech manufactures fermentation & semi-synthetic APIs which aim at dermatology, anti-biotics; mitochondria & memory health.
About the Company : Comhony Biotech is dedicated to supplying APIs and nutraceutical ingredients to worldwide clients in the pharmaceutical and nutraceutical sectors. Leveraging its proprietary techno...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : SUMAR Biotech LLP, registered in January 2018, is a startup approved by Gujarat State Biotechnology Mission. SUMAR Biotech LLP was started by emerging entrepreneurs and a team of y...
About the Company : Yacht Biotechnology is a bio-medicine company specializing in the research and development of new drugs, production process enhancement, drug structural analysis, and the establish...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The 5 patients in the age group birth to less than 3 months of age were not included in the efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single-dose DALVANCE regimen.
Lead Product(s): Dalbavancin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Dalvance
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Lead Product(s) : Dalbavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
DALVANCE FDA Approval Acute Bacterial Skin Structure Infections in Pediatric
Details : The 5 patients in the age group birth to less than 3 months of age were not included in the efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single-dose DALVANCE regimen.
Brand Name : Dalvance
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 23, 2021
Details:
The antibiotic dalbavancin has strong activity against gram-positive bacteria, including methicillin-resistant S. aureus, which suggests it could be an effective treatment for S. aureus bacteremia. NIH-supported trial will test dalbavancin in hospitalized adults.
Lead Product(s): Dalbavancin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Lead Product(s) : Dalbavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Trial of Existing Antibiotic for Treating Staphylococcus Aureus Bacteremia Begins
Details : The antibiotic dalbavancin has strong activity against gram-positive bacteria, including methicillin-resistant S. aureus, which suggests it could be an effective treatment for S. aureus bacteremia. NIH-supported trial will test dalbavancin in hospitalize...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 27, 2021
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?